RxDoctor Payments Data

Christopher Sinclair, MD

Neurology · Port Jefferson, NYNPI 1205987351

Payments from drug & device makers

$12,400in general payments, 2019–2025

Across 171 payments — averaging $72.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$8K
  • Teva Pharmaceuticals USA, Inc.$553
  • Amgen$459
  • Biogen$447
  • Novartis$159
  • AstraZeneca$152
  • plus $2K from 40 others

What the payments were for

  • Consulting fees$6,61353%
  • Speaking & faculty fees$200%
  • Travel & lodging$1,1339%
  • Food & beverage$4,63437%
  • Education$00%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,400 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$31,103
Medicare patients
222
Services billed
347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5051$1,331,570
PanzygaImmun Glob G(Igg)-Ifas/Glycine31$798,118
OctagamImmun Globg(Igg)/Malt/Iga Ov5024$590,738
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5021$499,867
GammakedImmune Globul G/Gly/Iga Avg 4619$374,182
Dimethyl Fumarate22$172,862
Kesimpta PenOfatumumab12$104,127
ValtocoDiazepam25$33,188
EliquisApixaban31$22,049
OxycontinOxycodone Hcl25$20,060
RexultiBrexpiprazole11$16,150
AptiomEslicarbazepine Acetate12$14,295
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone59$11,058
Pramipexole ErPramipexole Di-Hcl34$10,833
Aimovig AutoinjectorErenumab-Aooe13$9,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Octagam, Eliquis$51$1,410,90586 claims
Neurelis, Inc.Valtoco$125$33,18825 claims
Sunovion Pharmaceuticals Inc.Aptiom$150$14,29512 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$42$1,84233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Port Jefferson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →